The dose-limiting side effect of taxane, platinum-complex, and other kinds of anticancer drugs is a chronic, distal, bilaterally symmetrical, sensory peripheral neuropathy that is often accompanied by neuropathic pain. Work with animal models of these conditions suggests that the neuropathy is a consequence of toxic effects on mitochondria in primary afferent sensory neurons. If this is true, then additional mitochondrial insult ought to make the neuropathic pain worse. This prediction was tested in rats with painful peripheral neuropathy due to the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin. Rats with established neuropathy were given 1 of 3 mitochondrial poisons: rotenone (an inhibitor of respiratory Complex I), oligomycin (an inhibitor of adenosine triphosphate synthase), and auranofin (an inhibitor of the thioredoxin-thioredoxin reductase mitochondrial antioxidant defense system). All 3 toxins significantly increased the severity of paclitaxel-evoked and oxaliplatin-evoked mechano-allodynia and mechano-hyperalgesia while having no effect on the mechano-sensitivity of chemotherapy-naïve rats. Chemotherapy-evoked painful peripheral neuropathy is associated with an abnormal spontaneous discharge in primary afferent A fibers and C fibers. Oligomycin, at the same dose that exacerbated allodynia and hyperalgesia, significantly increased the discharge frequency of spontaneously discharging A fibers and C fibers in both paclitaxel-treated and oxaliplatin-treated rats, but did not evoke any discharge in naïve control rats. These results implicate mitochondrial dysfunction in the production of chemotherapy-evoked neuropathic pain and suggest that drugs that have positive effects on mitochondrial function may be of use in its treatment and prevention. Crown
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Introduction
Paclitaxel, oxaliplatin, and other chemotherapeutics produce chronic, bilaterally symmetrical, sensory, peripheral neuropathies that are often accompanied by neuropathic pain. Clinical descriptions of these neuropathies suggest that they produce similar neuropathic pain states [2,4,8,9,31]. It has been hypothesized that chemotherapy-evoked damage to mitochondria in primary afferent sensory axons leads to a chronic energy deficiency that is the proximate cause of the symptoms of the neuropathy [1,13,16,33,34]. Chronic deficits in peripheral nerve mitochondrial function (decreased respiration and adenosine triphosphate [ATP] production) have been shown in rats with paclitaxel-evoked and oxaliplatin-evoked painful neuropathies [34] .
If the mitotoxicity hypothesis is true, then the mitochondria in sensory axons of paclitaxel-treated and oxaliplatin-treated rats should be especially vulnerable to additional insult, and such an insult should make the neuropathic pain worse. The experiments reported here tested this prediction.
Methods
These experiments conformed to the ethics guidelines of the International Association for the Study of Pain 
